Suppr超能文献

寡核苷酸治疗策略在 polyQ 疾病中的评估。

An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases.

机构信息

Laboratory of Molecular Biomedicine, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Noskowskiego 12/14, 61-704 Poznan, Poland.

出版信息

BMC Mol Biol. 2012 Mar 7;13:6. doi: 10.1186/1471-2199-13-6.

Abstract

BACKGROUND

RNA interference (RNAi) and antisense strategies provide experimental therapeutic agents for numerous diseases, including polyglutamine (polyQ) disorders caused by CAG repeat expansion. We compared the potential of different oligonucleotide-based strategies for silencing the genes responsible for several polyQ diseases, including Huntington's disease and two spinocerebellar ataxias, type 1 and type 3. The strategies included nonallele-selective gene silencing, gene replacement, allele-selective SNP targeting and CAG repeat targeting.

RESULTS

Using the patient-derived cell culture models of polyQ diseases, we tested various siRNAs, and antisense reagents and assessed their silencing efficiency and allele selectivity. We showed considerable allele discrimination by several SNP targeting siRNAs based on a weak G-G or G-U pairing with normal allele and strong G-C pairing with mutant allele at the site of RISC-induced cleavage. Among the CAG repeat targeting reagents the strongest allele discrimination is achieved by miRNA-like functioning reagents that bind to their targets and inhibit their translation without substantial target cleavage. Also, morpholino analog performs well in mutant and normal allele discrimination but its efficient delivery to cells at low effective concentration still remains a challenge.

CONCLUSIONS

Using three cellular models of polyQ diseases and the same experimental setup we directly compared the performance of different oligonucleotide-based treatment strategies that are currently under development. Based on the results obtained by us and others we discussed the advantages and drawbacks of these strategies considering them from several different perspectives. The strategy aimed at nonallele-selective inhibiting of causative gene expression by targeting specific sequence of the implicated gene is the easiest to implement but relevant benefits are still uncertain. The gene replacement strategy that combines the nonallele-selective gene silencing with the expression of the exogenous normal allele is a logical extension of the former and it deserves to be explored further. Both allele-selective RNAi approaches challenge cellular RNA interference machinery to show its ability to discriminate between similar sequences differing in either single base substitutions or repeated sequence length. Although both approaches perform well in allele discrimination most of our efforts are focused on repeat targeting due to its potentially higher universality.

摘要

背景

RNA 干扰(RNAi)和反义策略为包括 CAG 重复扩展引起的多聚谷氨酰胺(polyQ)疾病在内的许多疾病提供了实验治疗药物。我们比较了几种基于寡核苷酸的策略在沉默引起多种 polyQ 疾病的基因方面的潜力,包括亨廷顿病和两种脊髓小脑共济失调,1 型和 3 型。这些策略包括非等位基因选择性基因沉默、基因替代、等位基因选择性 SNP 靶向和 CAG 重复靶向。

结果

使用多聚 Q 疾病的患者衍生细胞培养模型,我们测试了各种 siRNA 和反义试剂,并评估了它们的沉默效率和等位基因选择性。我们使用几种 SNP 靶向 siRNA 显示了相当大的等位基因区分,这些 siRNA 基于在 RISC 诱导切割部位与正常等位基因的弱 G-G 或 G-U 配对和与突变等位基因的强 G-C 配对。在 CAG 重复靶向试剂中,最强的等位基因区分是由类似于 miRNA 的功能试剂实现的,这些试剂结合到它们的靶标并抑制其翻译而不进行大量靶标切割。此外,吗啉代类似物在突变和正常等位基因区分方面表现良好,但在低有效浓度下有效递送到细胞中仍然是一个挑战。

结论

使用三种多聚 Q 疾病的细胞模型和相同的实验设置,我们直接比较了目前正在开发的几种基于寡核苷酸的治疗策略的性能。基于我们和其他人获得的结果,我们从几个不同的角度讨论了这些策略的优缺点。旨在通过靶向涉及基因的特定序列来非等位基因选择性抑制致病基因表达的策略是最容易实施的,但相关益处仍不确定。将非等位基因选择性基因沉默与外源性正常等位基因的表达相结合的基因替代策略是前一种策略的逻辑延伸,值得进一步探索。两种等位基因选择性 RNAi 方法都挑战细胞 RNA 干扰机制来展示其区分单碱基替换或重复序列长度不同的相似序列的能力。尽管这两种方法在等位基因区分方面表现良好,但我们的大部分努力都集中在重复靶向上,因为它具有更高的普遍性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aa0/3359213/2230c8e14551/1471-2199-13-6-1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验